JP Morgan Chase’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

JP Morgan Chase’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,300	Closed	-$116	–	8110
2023 Q3	$116	Sell	1,300 -1,852	-59%	-$172	﹤0.01%	6896
2023 Q2	$290	Buy	3,152 +1,852	+142%	+$295	﹤0.01%	6597
2023 Q1	$0	Hold	1,300	–	–	﹤0.01%	7563
2022 Q4	$0	Buy	1,300 +250	+24%	+$63	﹤0.01%	7402
2022 Q3	$0	Hold	1,050	–	–	﹤0.01%	7194
2022 Q2	$1K	Hold	1,050	–	–	﹤0.01%	6420
2022 Q1	$1K	Hold	1,050	–	–	﹤0.01%	6530
2021 Q4	$1K	Hold	1,050	–	–	﹤0.01%	6593
2021 Q3	$2K	Hold	1,050	–	–	﹤0.01%	6365
2021 Q2	$2K	Sell	1,050 -250	-19%	-$442	﹤0.01%	6229
2021 Q1	$3K	Hold	1,300	–	–	﹤0.01%	5925
2020 Q4	$3K	Hold	1,300	–	–	﹤0.01%	5507
2020 Q3	$4K	Sell	1,300 -150	-10%	-$538	﹤0.01%	5352
2020 Q2	$6K	Buy	1,450 +150	+12%	+$287	﹤0.01%	5180
2020 Q1	$1K	Sell	1,300 -5,955	-82%	-$6.57K	﹤0.01%	5233
2019 Q4	$9K	Buy	7,255 +5,955	+458%	+$5.14K	﹤0.01%	5410
2019 Q3	$1K	Hold	1,300	–	–	﹤0.01%	5680
2019 Q2	$1K	Hold	1,300	–	–	﹤0.01%	5732
2019 Q1	$4K	Hold	1,300	–	–	﹤0.01%	5648
2018 Q4	$3K	Buy	1,300 +250	+24%	+$1.03K	﹤0.01%	5584
2018 Q3	$5K	Hold	1,050	–	–	﹤0.01%	5570
2018 Q2	$5K	Buy	+1,050	New	+$5.49K	﹤0.01%	5441
2016 Q4	–	Sell	-136	Closed	-$2K	–	5244
2016 Q3	$2K	Sell	136 -1	-0.7%	-$13	﹤0.01%	4454
2016 Q2	$1K	Buy	+137	New	+$2.69K	﹤0.01%	4723
2013 Q4	–	Sell	-87,294	Closed	-$4.63M	–	4338
2013 Q3	$4.63M	Sell	87,294 -11,131	-11%	-$649K	﹤0.01%	2235
2013 Q2	$5.26M	Buy	+98,425	New	+$4.91M	﹤0.01%	2106

Other funds holding NAVB

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

JP Morgan Chase's NAVB Position: Q4 2023 in Review

JP Morgan Chase sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 1,300 shares — an estimated $116 sold.

JP Morgan Chase first reported a position in NAVB in Q2 2013 and held it in 26 quarters. The position peaked at $5.26M in Q2 2013. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.

JP Morgan Chase reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
JP Morgan Chase sold 1,300 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $116.
JP Morgan Chase first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 26 quarters.
JP Morgan Chase's Navidea Biopharmaceuticals Inc. position peaked at $5.26M in Q2 2013.
4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.

Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.